Stay informed on the latest Q3 2025 developments in the Inflation Reduction Act's impact on pharmaceutical supply chains, Medicare negotiation programs, and drug pricing reforms with the Mintz IRA Update.
North Carolina employers are shifting toward transparent pharmacy benefit managers to address rising drug costs and compliance risks. Learn how alternative PBMs impact insurance affordability and market dynamics.
Pharmaceutical companies are adopting direct-to-consumer drug sales, bypassing insurers and PBMs. This strategy impacts drug pricing, patient out-of-pocket costs, and insurance market dynamics in the U.S.
Explore key U.S. health policy and insurance sector updates covering veterans' care access reforms, behavioral health workforce challenges, prescription drug pricing shifts, public health threats, and innovation in healthcare delivery.
The AMA report reveals high market concentration among pharmacy benefit managers (PBMs), vertical integration with insurers, and calls for increased transparency and regulatory reforms to control drug prices and enhance competition.
The Trump administration proceeds with the third cycle of Medicare drug price negotiations, addressing Part B drug inclusion and sparking pharmaceutical industry concerns about pricing and implementation.
North Carolina moves forward with legislative efforts to regulate pharmacy benefit managers, aiming to increase transparency and fair reimbursement for independent pharmacies amid rising drug prices.
New analysis projects increased Medicare spending with expanded GLP-1 receptor agonist coverage for obesity, highlighting clinical benefits and financial challenges.
April 2025 update on U.S. pharmaceutical regulation highlights executive orders, budget changes, CMS policies, IRA litigation, and 340B program developments shaping drug pricing and access.
